A high-concentration, cell-free topical cosmetic matrix containing 150 billion NTA-documented extracellular vesicles in a 1.8 mL professional-use vial.

Developed for licensed aesthetic professionals seeking a premium topical formulation with expanded application volume and lot-specific quality documentation.

Product Overview

BioLife Dermal Exosome Matrix 150B is a concentrated topical cosmetic formulation designed for professional aesthetic environments.

Each 1.8 mL vial contains 150 billion extracellular vesicles derived from three-dimensional bioreactor-cultured Wharton’s Jelly hUCT-MSC source cells.

The larger application volume supports smooth and even topical coverage while maintaining a high extracellular-vesicle concentration.

This product is supplied in a liquid cryopreserved format and contains no live or viable cells.

Product Specifications

• Extracellular-Vesicle Count: 150 billion per vial
• Fill Volume: 1.8 mL
• Source: Wharton’s Jelly hUCT-MSC source cells
• Culture Method: Three-dimensional bioreactor culture
• Format: Liquid cryopreserved topical matrix
• Formulation: Cell-free
• Intended Use: Professional topical cosmetic use

Product Highlights

• 150 billion extracellular vesicles per vial
• Particle count documented through Nanoparticle Tracking Analysis
• Generous 1.8 mL professional-use volume
• Wharton’s Jelly hUCT-MSC source
• Three-dimensional bioreactor-cultured source cells
• Liquid cryopreserved formulation
• Cell-free cosmetic matrix
• Xeno-free and serum-free processing
• Endotoxin evaluation
• Sterility and mycoplasma testing
• Lot-specific Certificate of Analysis

Professional Cosmetic Use

The BioLife Dermal Exosome Matrix 150B is intended for licensed professionals who require a high-count topical cosmetic matrix with sufficient volume for broader application areas.

It may be incorporated into professionally directed aesthetic skin-care services and topical post-service routines when permitted by applicable regulations, product instructions, and professional scope-of-practice requirements.

Product selection, application, and professional-use decisions remain the responsibility of the qualified practitioner.

Quality Documentation

Each released lot may be accompanied by a Certificate of Analysis documenting applicable quality and release specifications.

Lot-specific documentation may include:

• NTA-documented particle count
• Particle-size distribution
• Sterility results
• Mycoplasma results
• Endotoxin evaluation
• Lot identification
• Storage requirements
• Expiration or use-by information

Storage and Handling

This product should be transported frozen using a validated cold chain. Store it at the temperature stated in the accompanying Certificate of Analysis and handling documentation.

Transfer the vial to the required storage environment immediately after delivery.

Do not refreeze after thawing. Use the product within the documented post-thaw period and follow all lot-specific storage and handling instructions.

Important Notice

For professional topical cosmetic use only.

Not for injection, implantation, intravenous administration, or therapeutic use.

This product is not an FDA-approved drug or therapeutic agent and is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.

BioLife Science does not provide dosing, administration, treatment, or clinical-use recommendations through this product listing.